A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Withdrawn before enrolling · Phase 3

Conditions studied: Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut

In brief

MP-101 will be evaluated in this study to see if it is safe and tolerable.

Key facts

Study ID

NCT02246816

Run by

Marathon Pharmaceuticals, LLC

People needed

0

Starts

2015-02-01

Expected to finish

2018-02-01

Last updated by the study team

2015-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be male or female adults, 18 years of age or older
• Have SBS that is inadequately controlled on current antidiarrheal medication (e.g., loperamide or diphenoxylate), including subjects with ileostomies
• Must have been deemed a completer of study protocol MP-101-CL-001.
• Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months of natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy)
• Females of childbearing potential must agree to use 1 of the following acceptable birth control methods:
• Surgically sterile (hysterectomy or bilateral oophorectomy)
• Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation)
• Intrauterine device (IUD) in place for at least 3 months
• Abstinence (not having sexual intercourse)
• Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion
• Stable hormonal contraceptive for at least 3 months prior to study and through study completion
• Vasectomized partner
• Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Visit 1.
• Be able to understand and provide signed informed consent

You may not qualify if…

• Have any history of or active neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease that is considered clinically significant, is not currently controlled by medication, and is stable as deemed by the Investigator
• Are currently taking antibiotics for bacterial overgrowth
• Have known or suspected pregnancy, planned pregnancy, or lactation
• Have a planned surgery during the course of the study
• Have a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk

Where it is running

• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Regional Infectious Disease Infusion Center — Lima, Ohio, United States
• Vanderbilt Center for Human Nutrition — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.